Abstract
JAMA. 2026 Nov 19. doi: 10.1001/jama.2026.24780. Online ahead of print.
ABSTRACT
IMPORTANCE: Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that cannot accurately be diagnosed during life due to the absence of in vivo biomarkers for CTE neuropathology.
OBJECTIVE: To evaluate plasma endogenously cleaved microtubule-binding region tau (eMTBR-tau) as a candidate biomarker for CTE tau tangle neuropathology.
DESIGN, SETTING, AND PARTICIPANTS: This case series included 21 former American-style football players who completed a blood draw as part of participation in clinical research at Boston University beginning April 17, 2008, and who subsequently died, donated their brain, and had completed autopsy by October 9, 2026.
EXPOSURES: Plasma eMTBR-tau nucleic acid-linked immunosandwich assay single-plex immunoassay and plasma phosphorylated tau 217 (p-tau217) (SP-X n = 20; Elecsys n = 1).
MAIN OUTCOMES AND MEASURES: CTE status and stage. Cumulative neuropathologic tau burden scores ranged from 0 to 33 (higher scores indicate tau burden; 0, no tau burden).
RESULTS: Among 21 male brain donors (median age at blood draw, CTE positive: 68 years [IQR, 61-77]; CTE negative: 49 years [IQR, 47-56]), 18 had a neuropathologic diagnosis of CTE. Of these participants, 16 had a diagnosis of high-stage CTE (stage IV = 8, stage III = 8); and 2, of low-stage CTE (stage II = 1, stage I = 1). Five CTE-positive participants had intermediate or high Alzheimer disease neuropathologic change (ADNC). Plasma eMTBR-tau concentration was significantly higher in CTE-positive participants (median, 0.019 pg/mL [IQR, 0.004-0.030]) compared with CTE-negative participants (0.001 pg/mL [IQR, 0.001-0.001]; β = 1.61 [95% CI, 0.51-2.70]). Plasma eMTBR-tau concentrations were highest among CTE-positive participants with comorbid ADNC (0.082 pg/mL [IQR, 0.059-0.131]) and intermediate among those with high-stage CTE without ADNC (n = 11; median, 0.009 pg/mL [IQR, 0.004-0.021]). Plasma eMTBR-tau concentration was significantly higher in high-stage CTE (median, 0.021 pg/mL [IQR, 0.006-0.038]) compared with low-stage CTE (median, 0.001 pg/mL [IQR, 0.001-0.002]; β = 1.79 [95% CI, 0.45-3.13]) or no CTE (median, 0.001 pg/mL [IQR, 0.001-0.001]; β = 1.78 [95% CI, 0.85-2.71]). Differences remained significant after exclusion of 5 cases with comorbid ADNC. Plasma eMTBR-tau concentration was associated with higher cumulative neuropathologic tau burden score across 11 brain regions (β = 0.71 [95% CI, 0.38-1.05]). Plasma p-tau217 concentration was positively associated with eMTBR-tau (β = 0.68 [95% CI, 0.32-1.04]) but was not associated with CTE. P-tau217 concentrations were in the negative range (n = 11) or intermediate range (n = 5) for participants without ADNC copathology. Four participants with ADNC had p-tau217 concentrations in the positive range; and 1, in the intermediate range.
CONCLUSIONS AND RELEVANCE: Participants with high-stage CTE had higher concentrations of plasma eMTBR-tau than those with low-stage or no CTE; concentrations were highest among those with CTE and comorbid ADNC. Plasma eMTBR-tau may represent a feasible biomarker candidate for high-stage CTE tau tangle neuropathology. Larger autopsy and clinical validation studies are needed to establish overall diagnostic accuracy and specificity of plasma eMTBR-tau for CTE neuropathology, in addition to the associated prognostic and clinical implications.
PMID:43056497 | DOI:10.1001/jama.2026.24780
UK DRI Authors